Survival comparisons based on patients with a GRS in the extreme quartiles in the Discovery cohort
| N patients | Mean age at event* (mean survival†) | HR (95% CI) | P value‡ | |||
| Affected | Unaffected | High quartile | Low quartile | |||
| First SDI score | 124 | 92 | 43 (51) | 51 (59) | 1.51 (1.04 to 2.25) | 3.7×10–2 |
| First CVE | 114 | 308 | 45 (64) | 51 (70) | 1.65 (1.03 to 2.64) | 2.6×10–2 |
| First AE | 72 | 310 | 52 (69) | 58 (78) | 2.16 (1.21 to 3.87) | 9.7×10–3 |
| First VTE | 60 | 322 | 39 (75) | 46 (79) | 1.30 (0.78 to 2.17) | 3.0×10–1 |
| Onset of ESRD | 14 | 245 | 43 (82) | 64 (92) | 6.78 (1.78 to 26.86) | 6.5×10–3 |
| Overall mortality | 50 | 379 | 66 (76) | 66 (82) | 1.83 (1.02 to 3.30) | 4.3×10–2 |
Patients in the extreme quartiles were included as affected individuals if they met the criteria for the examined manifestation; otherwise as censored individuals.
Values in bold indicate p<0.05.
*The mean age at the event includes only affected individuals.
†The mean survival is defined as the age at which 50% of individuals in each quartile are affected by the examined event.
‡Unadjusted.
AE, arterial event (myocardial infarction or ischaemic cerebrovascular disease); CVE, cardiovascular event (AE or VTE); ESRD, end-stage renal disease; GRS, genetic risk score; SDI, SLICC Damage Index29 ; VTE, venous thromboembolic event (deep vein thrombosis or pulmonary embolism).